ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,782.76
      1.23%
      US Tech 100
      19,692.40
      1.30%
      Dow Jones
      42,221.88
      1.02%
      Brent Oil
      75.39
      0.37%
      Bitcoin
      69,589.49
      2.61%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. ImmunityBio Inc (IBRX) Quote

      ImmunityBio Inc

      ImmunityBio Inc (IBRX)

      NASDAQ
      5.44
      0.24
      (4.62%)
      At close: November 05 4:00PM
      Delayed by 15 minutes
      5.48
      0.04
      ( 0.74% )
      After Hours: 5:55PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      5.48
      Bid
      5.41
      Ask
      5.48
      Volume
      4,998,264
      5.00 Day's Range 5.54
      2.665 52 Week Range 10.53
      Market Cap
      3.817B
      Previous Close
      5.20
      Open
      5.11
      Last Trade
      8
      @
      5.43
      Last Trade Time
      17:50:50
      Financial Volume
      $ 26,681,291
      VWAP
      5.3381
      Average Volume (3m)
      4,830,829
      Shares Outstanding
      696,533,418
      Dividend Yield
      -
      PE Ratio
      -38.80
      Earnings Per Share (EPS)
      -0.84
      Revenue
      622k
      Net Profit
      -583.2M

      About ImmunityBio Inc

      ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cel... ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.immunitybio.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      ImmunityBio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IBRX. The last closing price for ImmunityBio was $5.20. Over the last year, ImmunityBio shares have traded in a share price range of $ 2.665 to $ 10.53.

      ImmunityBio currently has 696,533,418 shares outstanding. The market capitalization of ImmunityBio is $3.62 billion. ImmunityBio has a price to earnings ratio (PE ratio) of -38.80.

      Ask ADVFN Intelligence (AI)

      IBRX Latest News

      More News

      First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

      Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent of Africa...

      October 24 2024
      Business Wire

      ImmunityBio to Participate in the Jefferies London Healthcare Conference

      Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place...

      October 21 2024
      Business Wire

      ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer 

      Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in 2nd and 3rd line NSCLC cancer patients who progressed on checkpoint...

      September 09 2024
      Business Wire

      ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

      ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval Global expansion of commercial and clinical bladder cancer programs Filing process...

      August 12 2024
      Business Wire

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 12 2024
      Edgar (US Regulatory)

      ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

      The QUILT 502 trial is testing ImmunityBio’s N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for endometrial cancer, a gynecological cancer with lower survival rates...

      August 06 2024
      Business Wire

      Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

      Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm PR Newswire NEW YORK, July 25, 2024 NEW YORK, July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law...

      July 25 2024
      PR Newswire (US)

      Form 8-K - Current report

      July 17 2024
      Edgar (US Regulatory)

      ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

      Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer...

      June 20 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      June 13 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.77-12.326.256.3290214.9675529855.45431796CS
      42.0358.84057971013.457.483.193986405875.14074648CS
      121.0724.26303854884.417.483.193948308294.58683416CS
      26-3.73-40.49945711189.219.47583.193941796435.5133303CS
      521.6944.59102902373.7910.532.66548983195.45670661CS
      156-3.2-36.8663594478.6810.531.2134555094.45535357CS
      260-31.07-85.006839945336.5540.8341.2130247655.19350034CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ARBBARB IOT Group Ltd
      $ 1.29
      (128.52%)
      		12.4M
      QLYSQualys Inc
      $ 152.11
      (18.62%)
      		116.08k
      ELWSEarlyworks Co Ltd
      $ 4.96
      (16.71%)
      		276.09k
      TMCITreace Medical Concepts Inc
      $ 6.60
      (14.58%)
      		55.76k
      PRQRProQR Therapeutics NV
      $ 4.0455
      (13.00%)
      		265
      EXASEXACT Sciences Corporation
      $ 49.98
      (-30.11%)
      		1.71M
      SMCXDefiance Daily Target 2X Long SMCI ETF
      $ 1.7298
      (-27.93%)
      		4.57M
      AVNWAviat Networks Inc
      $ 16.50
      (-21.17%)
      		28.47k
      NVOSNovo Integrated Sciences Inc
      $ 0.1245
      (-16.44%)
      		341.54k
      SMCISuper Micro Computer Inc
      $ 23.6899
      (-14.48%)
      		23.61M
      SMCISuper Micro Computer Inc
      $ 23.6899
      (-14.48%)
      		23.61M
      ARBBARB IOT Group Ltd
      $ 1.29
      (128.52%)
      		12.4M
      ELABElevai Labs Inc
      $ 0.0223
      (4.21%)
      		10.64M
      DJTTrump Media and Technology Group Corporation
      $ 34.60
      (1.94%)
      		7.01M
      LILMLilium NV
      $ 0.0538
      (3.46%)
      		5.83M

      IBRX Discussion

      View Posts
      glenn1919 glenn1919 1 week ago
      IBRX........................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      TrendTrade2016 TrendTrade2016 2 weeks ago
      IBRX ROCKET SHIP
      👍️0
      TrendTrade2016 TrendTrade2016 2 weeks ago
      IBRX PUSH PUSH PUSH
      👍️0
      glenn1919 glenn1919 2 weeks ago
      IBRX...................................https://stockcharts.com/h-sc/ui?s=IBRX&p=W&b=5&g=0&id=p86431144783
      👍️0
      TrendTrade2016 TrendTrade2016 2 weeks ago
      IBRX BIO BEAST
      👍️0
      tw0122 tw0122 2 weeks ago
      Not bad $5.13 + 28%
      👍️0
      jondoeuk jondoeuk 4 weeks ago
      A case report. From it: ''Here, we report the compassionate use treatment of this combination in a patient with recurrent, metastatic pancreatic cancer (mPC) after 3 lines of therapy. Under the initial single-patient Investigational New Drug (spIND) protocol, the patient received N-803, PD-L1 t-haNK cells, and the albumin doxorubicin conjugate aldoxorubicin for ~27 months. The patient's disease became stable on this regimen, and a transient complete response was observed by ~14 months of therapy. Due to progression, a second spIND protocol was designed whereby the patient received E-EDV-D682 plus EDV-GC for more than 24 months, which resulted in stable disease and the patient's continued survival at the time this report was written.'' https://academic.oup.com/oncolo/advance-article/doi/10.1093/oncolo/oyae267/7814737
      👍️ 1
      aBeezlee aBeezlee 1 month ago
      $2 would be great. We'll see.
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 1 month ago
      Wait until it hits $2.50

      Hold!
      👍️0
      axelvento axelvento 2 months ago
      bouncer$ ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

      https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/
      👍️0
      Monksdream Monksdream 2 months ago
      IBRX under $4
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 months ago
      Down and down, is approval for other cancer expected in June dead?
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 months ago
      Why did IBRX tank so badly in mid August?
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 3 months ago
      IBRX at $4

      Wow. Where is the pancreatic cancer approval expected in June?

      👍️0
      Monksdream Monksdream 3 months ago
      IBRX under $6
      👍️0
      Monksdream Monksdream 4 months ago
      IBRX under $10
      👍️0
      jgrabar jgrabar 4 months ago
      Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ImmunityBio, Inc. (IBRX)
      See https://grabarlaw.com/the-latest/immunitybio-shareholder-investigation/
      👍️0
      tw0122 tw0122 5 months ago
      09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.

      The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
      👍️0
      Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 5 months ago
      Any thoughts on how much revenue FDA approval will bring?
      👍️0
      wrk_SATX wrk_SATX 5 months ago
      Still +54M shares short and time is ticking. 80% inside ownership with a small float.
      👍️0
      saigai saigai 6 months ago
      up and down.. no problem.. ima staying put
      👍️0
      saigai saigai 6 months ago
      we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike
      👍️0
      carldfw carldfw 6 months ago
      Pancreatic Cancer next!!
      I like Oncolytics on that list
      👍️0
      Tahoe2468 Tahoe2468 6 months ago
      7. ImmunityBio Inc (NASDAQ:IBRX)
      Float Shorted: 40.37%

      With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.
      👍️0
      jondoeuk jondoeuk 6 months ago
      From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

      What happened?
      👍️0
      jondoeuk jondoeuk 6 months ago
      Nothing listed in the pipeline.
      👍️0
      Tahoe2468 Tahoe2468 6 months ago
      Pancreatic Cancer next!! WOW!!

      https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html
      👍️0
      TrendTrade2016 TrendTrade2016 6 months ago
      IBRX monster bio on the weekly break out
      👍️0
      MiamiGent MiamiGent 6 months ago
      IBRX Friday Close $7.35+$2.24 (+43.84%)

      This morning Pre-Mkt
      Bid x Size
      $8.13 x 2
      Ask x Size
      $8.20 x 212
      Volume
      862,349
      90 Day Avg. Vol.
      4,851,152

      Bona fide squeeze underway. Millions of shares short are trapped.
      👍️ 1
      carldfw carldfw 6 months ago
      Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
      pancreatic cancer
      . The company's combination immunotherapy
      , Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.
      👍️0
      martind18 martind18 6 months ago
      That’s because IHUB is for pump and dumps.
      👍️ 2
      Atom Smasher Atom Smasher 6 months ago
      Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40
      👍️ 2
      Monksdream Monksdream 6 months ago
      This a simple bar/volume with 60-minute intervals


      The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
      This a link for the sector that is made up 459 tickers
      https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

      I have a free membership so I can use the flipcharts function for the past six months of price discovery
      One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
      The best time to sell was at the peak last March which isn’t that long ago
      I can observe the same recurring pattern in the more than 200 tickers I flipped through
      👍️0
      Atom Smasher Atom Smasher 6 months ago
      https://www.barchart.com/stocks/quotes/IBRX/opinion
      👍️0
      Monksdream Monksdream 6 months ago
      IBRX in the Barchart Top 10
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️ 1
      axelvento axelvento 6 months ago
      Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..." pic.twitter.com/DIVc3A8luy— Yahoo Finance (@YahooFinance) April 23, 2024
      👍️ 1
      Pt3 Pt3 6 months ago
      Welcome
      👍️0
      martind18 martind18 6 months ago
      FDA approval!

      https://www.investorsobserver.com/news/qm-news/8088196297645818
      👍️0
      axelvento axelvento 7 months ago
      The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.
      👍️0
      Monksdream Monksdream 8 months ago
      IBRX chart
      👍️0
      Spideyboy Spideyboy 8 months ago
      Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

      My concern just stems from the bottom of the article stating.

      "Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
      https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

      There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

      I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

      Looking to be convinced wrong on the above :)
      👍️0
      Monksdream Monksdream 8 months ago
      Early Barchart 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      brogers_1 brogers_1 9 months ago
      Research tool: https://tradingtimeline.com/ibrx.html
      👍️0
      martind18 martind18 10 months ago
      https://www.oberlandcapital.com/news-post/immunitybio-announces-320-million-investment-by-oberland-capital/
      👍️0
      mick mick 10 months ago
      https://www.otcmarkets.com/stock/IBRX
      👍️0
      pilotnick pilotnick 11 months ago
      This stock is ready to breakout, did awesome today!!
      👍️0
      mick mick 1 year ago
      https://www.otcmarkets.com/stock/IBRX
      👍️0
      da_stock_analyst da_stock_analyst 1 year ago
      #IBRX 🔥 this stock can go crazy with 30% short interest! $IBRX
      👍️0
      da_stock_analyst da_stock_analyst 1 year ago
      #IBRX 🔥 30% short interest and gap fill possibilities for big move! $IBRX
      👍️0
      gail gail 1 year ago
      yup, i see that but….

      ….

      i didnt like how each time it runs, they yank it right back down, so i moved on but im happy it ran for you some. just be careful, they dont seem to last long.
      👍️0

      Your Recent History

      NASDAQ
      IBRX
      ImmunityBio
      Delayed Upgrade Clock